DJIA 17,826.82 16.76 0.09%
NASDAQ 4,738.98 26.01 0.55%
S&P 500 2,068.10 4.60 0.22%
market minute promo

ImmunoGen (NASDAQ: IMGN)



company name or ticker

Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher

Higher research and development costs coupled with an absence of milestone and license fee revenue sends ImmunoGen's loss markedly higher.

Why ImmunoGen (IMGN) Stock Is Down Today

Sector Update: Healthcare Shares Flat to Lower Pre-Market; ImmunoGen's Q3 Net Loss Widens From Year

Sector Update: Healthcare Shares Flat to Lower Pre-Market; ImmunoGen's Q3 Net Loss Widens From Year Prior

Sector Update: Healthcares

ImmunoGen, Inc. Discusses Q3 2014 Results (Webcast)

Spectrum Pharma Candidate Gets Positive Data - Analyst Blog

Biodel, HEC Pharm Ink Deal - Analyst Blog

The Fool Looks Ahead

Let's look at the stocks that will be making news in the week ahead.

Zogenix Shares Soar on Massachusetts Developments - Analyst Blog

Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape

See More Articles...